LATE-BREAKING ABSTRACT: Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 2-year results from the CHEST-2 long-term extension
G. Simonneau, A. M. D¿Armini, H. A. Ghofrani, F. Grimminger, M. M. Hoeper, P. Jansa, N. H. Kim, C. Wang, M. Wilkins, A. Fritsch, N. Davie, P. Colorado, E. Mayer (Le Kremlin¿Bicêtre, France; Pavia, Italy; Giessen, Hannover, Wuppertal, Bad Nauheim, Germany; London, United Kingdom; Prague, Czech Republic; La Jolla, United States Of America; Beijing, China; Barcelona, Spain)
Source: International Congress 2014 – New technologies and biomarkers in lung disease
Session: New technologies and biomarkers in lung disease
Session type: Poster Discussion
Number: 1802
Disease area: Pulmonary vascular diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Simonneau, A. M. D¿Armini, H. A. Ghofrani, F. Grimminger, M. M. Hoeper, P. Jansa, N. H. Kim, C. Wang, M. Wilkins, A. Fritsch, N. Davie, P. Colorado, E. Mayer (Le Kremlin¿Bicêtre, France; Pavia, Italy; Giessen, Hannover, Wuppertal, Bad Nauheim, Germany; London, United Kingdom; Prague, Czech Republic; La Jolla, United States Of America; Beijing, China; Barcelona, Spain). LATE-BREAKING ABSTRACT: Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 2-year results from the CHEST-2 long-term extension. Eur Respir J 2014; 44: Suppl. 58, 1802
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: